ArticleBMC cancer2025
NHP2 and PRPF4 are hub genes associated with the prognosis of colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Colorectal cancer-derived exosomal ETS2 promotes macrophage M2 polarization by transcriptionally activating PRPF4.Human cell · 2026Article
- Bioinformatics-driven discovery and experimental validation of differentially expressed genes in colorectal adenomas.Molecular biology reports · 2026Article
- CK2α Overexpression in Colorectal Cancer: Evidence for Sex- and Age-Linked Differences.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThere is an urgent need to identify more accurate and practical prognostic markers for improving the diagnosis and treatment outcomes of colorectal cancer (CRC). This study aimed to identify hub genes of CRC and to evaluate their clinical significance.
methodsProteomics analysis was performed on human CRC tissues and adjacent normal tissues, with bioinformatic screening applied to identify hub genes. Differential mRNA/protein expression of the hub genes between CRC tissues and adjacent tissues was validated using public databases combined with RT-qPCR. Potential upstream regulators of hub genes were predicted through integrated analysis of the TF-target database, Starbase, and Comparative Toxicogenomics Database (CTD). Protein expression levels of the hub genes were assessed in 100 tissues by immunohistochemistry (IHC)with semi-quantitative scoring. Prognostic utility of the screened hub genes was evaluated through receiver operating characteristic (ROC) curve analysis and overall survival (OS) stratification.
resultsNHP2 (a small nucleolar ribonucleoprotein) and PRPF4 (pre-mRNA processing factor 4) were identified as two hub genes/proteins in CRC. Both genes exhibited significant upregulation in CRC tissues at transcriptional and translational levels compared with adjacent tissues. ROC analysis demonstrated strong diagnostic potential: NHP2 AUC (area under curve) = 0.819 (95% CI: 0.639-0.958; P < 0.001) and PRPF4 AUC = 0.917 (95% CI: 0.785-1.000; P < 0.001). NHP2 and PRPF4 shared common regulators and exhibited a positive correlation in their expression levels.Clinically, patients with dual high expression of NHP2 and PRPF4 showed markedly reduced prognosis versus single-high or dual-low groups.
conclusionsConcurrent overexpression of NHP2 and PRPF4 is significantly associated with worse prognosis in CRC. Combined detection of NHP2 and PRPF4 is potentially a valuable prognostic marker of CRC compared to individual assessments. Our findings contribute to the growing body of evidence supporting multi-marker strategies for prognostic evaluation in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.